US Edition
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The draft order gives companies a path to avoid the levy by striking pricing deals or moving production to the United States.
- President Donald Trump is expected to announce 100% tariffs on imported patented drugs and active ingredients as soon as today, Thursday, according to a draft order, unless companies secure pricing deals with the White House.
- The administration aims to pressure pharmaceutical companies into "Most Favored Nation" pricing agreements, which tie U.S. drug costs to cheaper international prices and exempt participating manufacturers from these new levies.
- By moving production to the U.S., companies can cut the tariff rate to 20% for four years, though failure to negotiate with the Department of Health and Human Services results in the full 100% tax.
- Since November, over a dozen drugmakers—including Eli Lilly, Pfizer, and Novo Nordisk—have inked deals to lower medicine prices, as 61% of Americans report high concern about healthcare affordability.
- Mark Cuban has defended TrumpRx, stating, "Anything that opens the door for lower price medications I'm a fan of," regarding his support for the administration's strategy.
14 Articles
14 Articles
Trump set to impose new tariffs on certain pharmaceutical drugs
President Donald Trump plans to impose new tariffs on pharmaceutical companies that have not struck deals to sell their drugs directly to consumers as part of his “Most Favored Nation” pricing initiative, according to a draft of an order obtained by CNN.
Trump Set to Impose New Tariffs on Some Drugs
CNN: “President Donald Trump plans to impose new tariffs on pharmaceutical companies that have not struck deals to sell their drugs directly to consumers as part of his 'Most Favored Nation' pricing initiative.”“Those medications would be hit with a 100% tariff, according to the draft orde
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
The Trump administration is reportedly preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House. The announcement could come as soon as Thursday, Bloomberg reported, citing people familiar with the matter. The tariffs stem from a Section 232 investigation under the Trade Expansion Act, invoking national security grounds. Companies neither holding agreements nor in active negotiations…
According to the Financial Times, the new tariffs will be announced shortly and would affect all pharma companies that have not signed agreements with the White House.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
